FDA approves Edurant Ped (rilpivirine) for certain pediatric patients Living with HIV-1 – Johnson & Johnson
Johnson & Johnson announced that the FDA has approved Edurant Ped (rilpivirine) for the treatment of HIV-1 in combination with other antiretroviral therapies (ARVs) in treatment-naïve children (with… read more.
